Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG (BAYN)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Bayer AG : Expansion of germplasm-pool for wheat:

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/14/2011 | 11:30am CET
Bayer CropScience acquires access to wheat germplasm from leading Romanian agricultural research institution
Monheim, October 14, 2011 – Bayer CropScience and the National Agricultural Research and Development Institute (NARDI) in Fundulea/Romania have signed a license agreement. With this agreement, Bayer gains access to winter wheat germplasm of NARDI, the leading Romanian agricultural research institution. Its germplasm pool is renowned world-wide for its winter hardiness, high tolerance against drought, broad disease resistance and good milling and baking quality. Financial details were not disclosed.
“Improving the productivity of wheat cropping will be critical to achieving global food security. Our customers have turned to us to find new ways to help them, we have listened and are building a world-class research platform for wheat genetics. Our agreement with NARDI is another key building block in this strategy“, said Hartmut van Lengerich, Head of Cereals and Fungicides at Bayer CropScience. “To speed up development of new varieties, we have already entered into collaborations with the best partners in wheat research and breeding, reaching from Australia to Israel, France and Ukraine to the United States – and now Romania.”
“Producing enough wheat to feed the world is an immense challenge and anyone willing to invest in the effort to meet this challenge is welcome”, said Marian Verzea, General Director of NARDI. “NARDI is proud that the wheat germplasm developed by its breeding program will be used to speed up genetic progress in breeding better wheat cultivars for other parts of the world, too.”
Key figures about wheat:
With about 25 percent of the global agricultural land under wheat cultivation, it is the largest cereal crop in terms of acreage and one of the world’s most important staple foods. Wheat is the second most-produced cereal crop after corn with more than 650 million tons produced every year. Wheat productivity is increasing at less than 1 percent annually, while the annual global demand is growing at approximately double that percentage. Main wheat producing regions are Australia, the Black Sea Region, China, the EU, India and North America.
About Bayer CropScience
Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer CropScience, a subgroup of Bayer AG with annual sales of EUR 6.830 billion (2010), is one of the world’s leading innovative crop science companies in the areas of crop protection, non-agricultural pest control, seeds and traits. The company offers an outstanding range of products and extensive service backup for modern, sustainable agriculture and for non-agricultural applications. Bayer CropScience has a global workforce of 20,700 and is represented in more than 120 countries. This and further news is available at: www.press.bayercropscience.com.
About NARDI
NARDI Fundulea is recognized as the main agricultural research unit in Romania, due to the results obtained in breeding and crop management research & development regarding cereals, industrial and forage crops. Results of wheat breeding have a special place in NARDI’s research portfolio. NARDI’s twenty nine common wheat cultivars released since 1957 have had the largest share of the Romanian wheat seed market for more than 30 years, while nine NARDI wheat cultivars have been released in other countries, such as Canada, Argentina, Hungary, Turkey. Further information is available at: www.incda-fundulea.ro
Find more information at www.bayercropscience.com.
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER AG
01/18DJBayer Joins Jobs Parade -- WSJ
01/18DJBAYER : Will Keep Monsanto Jobs in U.S., Trump Team Says -- 2nd Update
01/17DJBAYER : Will Keep Monsanto Jobs in U.S., Trump Team Says -- Update
01/17DJBAYER : Will Keep Monsanto Jobs in U.S., Trump Team Says
01/12 BAYER : Regorafenib from Bayer Granted Priority Review in the U.S. for Second-Li..
01/12 Bayer says had productive meeting with Trump over Monsanto deal
01/12 BAYER : CEOs of Monsanto and Bayer meet with Trump, press case for merger
01/11DJBAYER : Monsanto CEOs Pitch Deal to Trump
01/10 BAYER : MILITARY $6,894 Federal Contract Awarded to Bayer HealthCare
01/09 BAYER : Volker Koch-Achelpöhler to head Bayer’s EU Liaison Office in Bruss..
More news
Sector news : Pharmaceuticals - NEC
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/19 Davos CEOs 'go local' on supply chain in Trump era
01/19 GSK grabs Astra executive to replace pharma head
01/19DJGLAXOSMITHKLINE : Global Pharmaceuticals President Abbas Hussain to Leave -- Upd..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/18 Xbiotech Has A Great Upside Potential With Only Limited Downside After Reveal..
01/18 Bayer Has Little Upside Left
01/18 Vet med industry now dominated by four firms; further mergers unlikely
01/18 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q4 2016 Update
01/17 Bayer, Monsanto confirm spending, jobs plans after meeting Trump
Advertisement
Financials (€)
Sales 2016 46 746 M
EBIT 2016 8 695 M
Net income 2016 4 762 M
Debt 2016 15 852 M
Yield 2016 2,63%
P/E ratio 2016 17,58
P/E ratio 2017 15,71
EV / Sales 2016 2,14x
EV / Sales 2017 1,98x
Capitalization 84 349 M
More Financials
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 109 €
Spread / Average Target 6,5%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Human Resources, Technology & Sustainability
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG1.33%89 758
JOHNSON & JOHNSON-0.44%312 045
ROCHE HOLDING LTD.1.29%203 230
PFIZER INC.-1.39%194 369
NOVARTIS AG-3.71%189 507
MERCK & CO., INC.3.91%168 654
More Results